Neuroprotective effect of thalidomide on MPTP-induced toxicity

Neurotoxicology
Guadalupe PalenciaJulio Sotelo

Abstract

Thalidomide is a sedative with unique pharmacological properties; studies on epilepsy and brain ischemia have shown intense neuroprotective effects. We analyzed the effect of thalidomide treatment on the neurotoxicity caused by the administration of 1-methyl-4-phenyl-1,2,3,6-tetrahidropyridine (MPTP) in mice. Thalidomide was administered at two times; before and after the exposure to MPTP. In both circumstances thalidomide improved the neurotoxicity induced by MPTP as seen by a significant raise of the striatal contents of dopamine and simultaneous decrease of monoamine-oxidase-B (MAO-B). These results indicate that in the experimental model of Parkinson's disease the administration of thalidomide improves the functional damage on the nigrostriatal cell substratum as seen by the production of dopamine. This neuroprotective effect seems to be mediated by inhibition of excitotoxicity. Our results suggest that thalidomide could be investigated as potential adjuvant therapy for Parkinson's disease.

References

Jun 1, 1985·Journal of Pharmacological Methods·A Morinan, H M Garratt
Aug 15, 1984·Biochemical Pharmacology·R Hernández-MuñozV Chagoya de Sánchez
Nov 19, 1997·Neuroscience Letters·A BoireauA Impérato
Mar 13, 1998·Brazilian Journal of Medical and Biological Research = Revista Brasileira De Pesquisas Médicas E Biológicas·A L MoreiraG Kaplan
Jan 5, 2002·Journal of Neural Transmission·N Schmidt, B Ferger
Jun 19, 2002·The Journal of Biological Chemistry·Yael AvramovichMoussa B H Youdim
Jun 27, 2002·International Journal of Experimental Pathology·Oscar ArrietaJulio Sotelo
Nov 6, 2002·Journal of Experimental Therapeutics & Oncology·Guadalupe PalenciaJulio Sotelo
Mar 3, 2006·The Journal of Neuroscience : the Official Journal of the Society for Neuroscience·Mahmoud KiaeiM Flint Beal
Apr 24, 2007·Journal of the Neurological Sciences·Guadalupe PalenciaJulio Sotelo
Mar 20, 1964·Science·E HirschbergJ E Ultmann
Feb 5, 2008·Blood·Antonio PalumboJean-Luc Harousseau
Feb 21, 2008·PloS One·Jyothi K MallajosyulaJulie K Andersen
Mar 8, 2008·Nature Medicine·Meredith Wadman
Oct 23, 2010·Journal of Pain and Symptom Management·Eric E PrommerAndrew Wilcock
Nov 3, 2010·Epilepsy Research·Guadalupe PalenciaJulio Sotelo
May 20, 2011·Epilepsy Research·Guadalupe PalenciaJulio Sotelo
Jun 10, 2011·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Shakevia JohnsonXiao-Ming Ou
Jun 12, 2012·Oxidative Medicine and Cellular Longevity·Sonia Gandhi, Andrey Y Abramov
Dec 19, 2012·Biotechnic & Histochemistry : Official Publication of the Biological Stain Commission·Hk ElçioğluMa Karan
Apr 11, 2013·Drugs·Shelley Elkinson, Paul L McCormack

❮ Previous
Next ❯

Citations

May 23, 2018·International Journal of Molecular Sciences·Meng WeiHua Su
Mar 10, 2016·Neurotoxicity Research·Silvia Lima CostaJuan Segura-Aguilar
Oct 13, 2018·Journal of Medical Internet Research·Mengnan Zhao, Christopher C Yang
Mar 21, 2019·Reviews in Endocrine & Metabolic Disorders·Dannia Colín-Castelán, Silvio Zaina
Aug 22, 2018·Neural Regeneration Research·Bridget Martinez, Philip V Peplow
Dec 24, 2019·Frontiers in Cell and Developmental Biology·Yoo Jin JungNigel H Greig
Nov 15, 2020·International Journal of Molecular Sciences·Jinhao HuangHua Su
Dec 17, 2020·Frontiers in Neuroscience·Ji WangShaogang Qu

❮ Previous
Next ❯

Related Concepts

Related Feeds

Brain Ischemia

Brain ischemia is a condition in which there is insufficient blood flow to the brain to meet metabolic demand. Discover the latest research on brain ischemia here.

Basal Ganglia

Basal Ganglia are a group of subcortical nuclei in the brain associated with control of voluntary motor movements, procedural and habit learning, emotion, and cognition. Here is the latest research.